Groupe d'Etude en Oncologie du Quebec

Titre	Health Related Quality of Life (HRQL) and Symptom Assessment in Patients Diagnosed With Diffuse Intrinsic Pontine Glioma (DIPG) or Recurrent and Re-irradiated Brain Tumours and Their Caregivers: A Non-Therapeutic Study
Protocole ID	DIPG HRQOL
ClinicalTrials.gov ID	NCT04670016
Type(s) de cancer	Pédiatrique divers
Phase	Autres
Type étude	Autre
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL CHUL ET CENTRE MERE-ENFANT SOLEIL 2705 boulevard Laurier, Québec, QC, G1V 4G2
Ville	Québec
Investigateur(trice) principal(e)	Dre Valérie Larouche
Coordonnateur(trice)	Panagiota Giannakouros 418-525-4444 poste 40121
Statut	Actif en recrutement
Critètes d'éligibilité	Patient aged >2 and <21 years treated with a repeat course of radiation for DIPG or other recurrent or progressive brain tumour. Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia). Enrollment within 14 days of starting re-irradiation (RT2). Patients with malignant transformation of the first tumour are eligible. There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1. The patient is treated at a site where the study is approved by the local ethics board Consent, and, if applicable, assent, has been obtained according to institutional standards
Critètes d'exclusion	Inability to complete questionnaires in English or French.

Groupe d'étude en oncologie du Québec